Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Francesco Minuto"'
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 3 (2012)
Objective : To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope ® ) for the treatment of adult patients with growth hormone deficiency (GHD). Methods
Externí odkaz:
https://doaj.org/article/4379439b0acf48998b00dbf01211b032
Autor:
Tullio Florio, Diego Ferone, Gennaro Schettini, Renato Spaziante, Francesco Minuto, Jean-Louis Ravetti, Alessandra Dorcaratto, Gianluigi Zona, Carola Porcile, Alessandra Pattarozzi, Ralf Stumm, Adriana Bajetto, Federica Barbieri
Supplementary Data from Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e722483103d582620feb8948246decc
https://doi.org/10.1158/1078-0432.22439410
https://doi.org/10.1158/1078-0432.22439410
Autor:
Tullio Florio, Diego Ferone, Gennaro Schettini, Renato Spaziante, Francesco Minuto, Jean-Louis Ravetti, Alessandra Dorcaratto, Gianluigi Zona, Carola Porcile, Alessandra Pattarozzi, Ralf Stumm, Adriana Bajetto, Federica Barbieri
Purpose: Hypothalamic or locally produced growth factors and cytokines control pituitary development, functioning, and cell division. We evaluated the expression of the chemokine stromal cell–derived factor 1 (SDF1) and its receptor CXCR4 in human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ceae6e7454566c40a9b45b9dedb2752
https://doi.org/10.1158/1078-0432.c.6516877
https://doi.org/10.1158/1078-0432.c.6516877
Autor:
Annamaria Colao, Antoine Tabarin, Carla Scaroni, Marek Bolanowski, Véronique Kerlan, Beata Kos-Kudła, Francesco Minuto, Jan Komorowski, Wojciech Zgliczyński
Introduction: Long-acting repeatable (LAR) octreotide i.m. is a potent, synthetic somatostatin analogue (SSA) that requires less frequent dosing and offers quality of life (QoL) benefits in acromegaly patients compared to its shorter-acting predecess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39bf93edc1ad7099430c9e2f88674fee
http://hdl.handle.net/11577/3309709
http://hdl.handle.net/11577/3309709
Autor:
Eleonora Monti, Lorenzo Mortara, Massimo Giusti, Francesco Minuto, Gianmario Sambuceti, Giorgia Pera, Silvia Morbelli
Publikováno v:
Journal of Endocrinological Investigation. 37:1099-1108
Sorafenib has recently been recognized as an important standard option for the management of patients with differentiated thyroid cancer. Although data concerning cardiac safety are available in pan-tumor studies, no data are available on its use in
Autor:
Diego Ferone, Andrea Giusti, Giovanni Murialdo, Mara Boschetti, Francesco Minuto, Pietro Ameri
Publikováno v:
Clinical Endocrinology. 79:457-463
The interplay between vitamin D and IGF-I is complex and occurs at both endocrine and paracrine/autocrine levels. Vitamin D has been shown to increase circulating IGF-I and IGFBP-3, with the consistent finding of a positive correlation between vitami
Publikováno v:
L'Endocrinologo. 14:71-78
Grazie ai progressi dell’industria, i farmaci oggi a disposizione per la terapia medica dell’acromegalia sono diversificati e hanno permesso, rispetto al passato, e in associazione alla chirurgia, di aumentare la percentuale di pazienti che raggi
Autor:
Diego Ferone, Marica Arvigo, Francesco Minuto, Mara Boschetti, Federico Gatto, Manuela Albertelli
Publikováno v:
Expert Review of Endocrinology & Metabolism. 8:149-157
The actions of somatostatin (SRIF) are mediated by specific G protein-coupled receptors, named SRIF receptor (SSTR) subtypes 1, 2, 3 and 5. SRIF binding to SSTR activates a series of second messenger systems, resulting in the inhibition of calcium ch
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 3 (2012)
Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope®) for the treatment of adult patients with growth hormone deficiency (GHD). Methods: PA
Autor:
Federica Barbieri, Diego Ferone, Leo J. Hofland, Francesco Minuto, Tullio Florio, Federico Gatto, Massimo Giusti, Michael D. Culler, Jean Louis Ravetti, Roberto Würth, Gianluigi Zona, Stefan Schulz, Alexandru Saveanu, Monica Gatti
Publikováno v:
Clinical Endocrinology. 76:407-414
Context First-line therapy for thyrotropin-secreting pituitary adenomas (TSHomas) is neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically available sst(2) -preferring analogues, octreotide and lanreotide, induce no